Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Effects of a cream containing 5% hyaluronic acid mixed with a bacterial-wall-derived glycoprotein, glycyrretinic acid, piroctone olamine and climbazole on signs, symptoms and skin bacterial microbiota in subjects with seborrheic dermatitis of the face.

Puviani M, Campione E, Offidani AM, De Grandi R, Bianchi L, Bobyr I, Giannoni M, Campanati A, Bottagisio M, Bidossi A, De Vecchi E, Eisendle K, Milani M.

Clin Cosmet Investig Dermatol. 2019 May 2;12:285-293. doi: 10.2147/CCID.S205904. eCollection 2019.

2.

A starch, glycyrretinic, zinc oxide and bisabolol based cream in the treatment of chronic mild-to-moderate atopic dermatitis in children: a three-center, assessor blinded trial.

Licari A, Ruffinazzi G, DE Filippo M, Castagnoli R, Marseglia A, Agostinis F, Puviani M, Milani M, Marseglia GL.

Minerva Pediatr. 2017 Dec;69(6):470-475. doi: 10.23736/S0026-4946.17.05015-0.

PMID:
29181960
3.

Efficacy and Safety of Cream Containing Climbazole/Piroctone Olamine for Facial Seborrheic Dermatitis: A Single-Center, Open-Label Split-Face Clinical Study.

Youn HJ, Kim SY, Park M, Jung WH, Lee YW, Choe YB, Ahn KJ.

Ann Dermatol. 2016 Dec;28(6):733-739. Epub 2016 Nov 23.

4.

Clinical and instrumental evaluation of a new topical non-corticosteroid antifungal/anti-inflammatory/antiseborrheic combination cream for the treatment of mild-to-moderate facial seborrheic dermatitis.

Dall'Oglio F, Lacarrubba F, Luca M, Boscaglia S, Granger C, Micali G.

Clin Cosmet Investig Dermatol. 2019 Jan 24;12:103-108. doi: 10.2147/CCID.S186621. eCollection 2019.

5.

A novel cosmetic antifungal/anti-inflammatory topical gel for the treatment of mild to moderate seborrheic dermatitis of the face: an open-label trial utilizing clinical evaluation and erythema-directed digital photography.

Dall' Oglio F, Tedeschi A, Fusto CM, Lacarrubba F, Dinotta F, Micali G.

G Ital Dermatol Venereol. 2017 Oct;152(5):436-440. doi: 10.23736/S0392-0488.17.05539-0. Epub 2017 Jan 24.

PMID:
28121079
6.

Efficacy and tolerability of 1% ciclopirox shampoo in the treatment of moderate-to-severe scalp seborrheic dermatitis: a multicenter, prospective, assessor-blinded trial.

Veraldi S, Barbareschi M, Martella A, Milani M.

G Ital Dermatol Venereol. 2019 Jun;154(3):342-346. doi: 10.23736/S0392-0488.17.05623-1.

PMID:
31001967
7.
8.
9.

Topical pimecrolimus 1% cream for resistant seborrheic dermatitis of the face: an open-label study.

Ozden MG, Tekin NS, Ilter N, Ankarali H.

Am J Clin Dermatol. 2010;11(1):51-4. doi: 10.2165/11311160-000000000-00000.

PMID:
20000875
10.

Treatment of Seborrheic Dermatitis Using a Novel Herbal-based Cream.

Barak-Shinar D, Del Río R, Green LJ.

J Clin Aesthet Dermatol. 2017 Apr;10(4):17-23.

11.

Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk.

Rallis E, Nasiopoulou A, Kouskoukis C, Koumantaki E.

Drugs Exp Clin Res. 2004;30(5-6):191-5.

PMID:
15700745
13.

Local rhamnosoft, ceramides and L-isoleucine in atopic eczema: a randomized, placebo controlled trial.

Marseglia A, Licari A, Agostinis F, Barcella A, Bonamonte D, Puviani M, Milani M, Marseglia G.

Pediatr Allergy Immunol. 2014 May;25(3):271-5. doi: 10.1111/pai.12227.

14.

Comparison of different regimens of pimecrolimus 1% cream in the treatment of facial seborrheic dermatitis.

Zhao J, Sun W, Zhang C, Wu J, Le Y, Huang C, Liu Y, Xiang L.

J Cosmet Dermatol. 2018 Feb;17(1):90-94. doi: 10.1111/jocd.12353. Epub 2017 Jun 7.

PMID:
28589618
15.

Treatment of facial seborrheic dermatitis with pimecrolimus cream 1%: an open-label clinical study in Korean patients.

Kim BS, Kim SH, Kim MB, Oh CK, Jang HS, Kwon KS.

J Korean Med Sci. 2007 Oct;22(5):868-72.

16.

Efficacy of a film-forming medical device containing sunscreen (50+) and piroxicam 0.8% in actinic keratosis and field cancerization: a multicenter, assessor-blinded, 3 month trial.

Puviani M, Galloni C, Marchetti S, Sergio Pavone P, Lovati S, Pistone G, Caputo V, Tilotta G, Scarcella G, Campione E, Diluvio L, Garofalo V, Bianchi L, Milani M.

Curr Med Res Opin. 2017 Jul;33(7):1255-1259. doi: 10.1080/03007995.2017.1313212. Epub 2017 Apr 20.

PMID:
28358282
17.
18.

Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis.

Warshaw EM, Wohlhuter RJ, Liu A, Zeller SA, Wenner RA, Bowers S, Schultz JC, Katz HI, McCormick CL, Parneix-Spake A.

J Am Acad Dermatol. 2007 Aug;57(2):257-64. Epub 2006 Dec 22.

PMID:
17188780
19.

Brightening and Improvement of Facial Skin Quality in Healthy Female Subjects With Moderate Hyperpigmentation or Dark Spots and Moderate Facial Aging

Serra M, Bohnert K, Narda M, Granger C, Sadick N.

J Drugs Dermatol. 2018 Dec 1;17(12):1310-1315.

PMID:
30586263
20.

Effects of topical piroxicam and sun filters in actinic keratosis evolution and field cancerization: a two-center, assessor-blinded, clinical, confocal microscopy and dermoscopy evaluation trial.

Agozzino M, Russo T, Franceschini C, Mazzilli S, Garofalo V, Campione E, Bianchi L, Milani M, Argenziano G.

Curr Med Res Opin. 2019 Jun 13:1-8. doi: 10.1080/03007995.2019.1626227. [Epub ahead of print]

PMID:
31148490

Supplemental Content

Support Center